

Resource Summary Report

Generated by [nidm-terms](#) on Aug 10, 2026

PerCP anti-mouse CD4

RRID:AB_893323

Type: Antibody

Proper Citation

BioLegend Cat# 100432, RRID:AB_893323

Antibody Information

URL: http://antibodyregistry.org/AB_893323

Proper Citation: BioLegend Cat# 100432, RRID:AB_893323

Target Antigen: CD4

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PerCP anti-mouse CD4

Description: This monoclonal targets CD4

Target Organism: mouse

Clone ID: Clone GK1.5

Antibody ID: AB_893323

Vendor: BioLegend

Catalog Number: 100432

Alternative Catalog Numbers: 100431

Record Creation Time: 20250819T223909+0000

Record Last Update: 20250820T025234+0000

Ratings and Alerts

No rating or validation information has been found for PerCP anti-mouse CD4.

No alerts have been found for PerCP anti-mouse CD4.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 25 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Zha M, et al. (2026) Single-cell omics and flow cytometry identify distinct immune states of dural and brain-infiltrating IL-17-producing ?? T cells after experimental stroke. Journal of neuroinflammation, 23(1).

Lin X, et al. (2026) Spleen-targeted neoantigen mRNA vaccine induces ISG15+ CD8+ T cell-mediated tertiary lymphoid structure formation in hepatocellular carcinoma. Cell reports. Medicine, 7(5), 102754.

Pei Z, et al. (2026) STAT3 interference-driven nanomodulators reverse lipid metabolism-associated chemoresistance and potentiate metalloimmunotherapy in breast cancer. Cell reports. Medicine, 7(6), 102844.

Chen S, et al. (2026) PD-1 blockade unleashes local hepatitis B virus-related B cell response inhibiting hepatocellular carcinoma. Cancer cell.

Li D, et al. (2025) SOSTDC1 downregulation in CD4+ T cells confers protection against obesity-induced insulin resistance. Cell reports, 44(4), 115496.

Fan Y, et al. (2025) Itaconate transporter SLC13A3 confers immunotherapy resistance via alkylation-mediated stabilization of PD-L1. Cell metabolism, 37(2), 514.

Gao C, et al. (2025) Cancer vaccine from intracellularly gelated tumor cells functionalized with CD47 blockage and damage-associated molecular pattern exposure. Cell reports. Medicine, 6(5), 102092.

Huang F, et al. (2025) Bile acids activate cancer-associated fibroblasts and induce an immunosuppressive microenvironment in cholangiocarcinoma. Cancer cell, 43(8), 1460.

Cheung JF, et al. (2025) Distinct T cell functions enable efficient immunoediting and prevent tumor emergence of developing sarcomas. Cancer cell, 43(12), 2311.

Cheng JN, et al. (2025) Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclasts. Cancer cell, 43(6), 1093.

Tang Z, et al. (2025) Spatial transcriptomics reveals tryptophan metabolism restricting maturation of intratumoral tertiary lymphoid structures. *Cancer cell*, 43(6), 1025.

Bi Y, et al. (2024) Tumor-derived extracellular vesicle drug delivery system for chemo-photothermal-immune combination cancer treatment. *iScience*, 27(2), 108833.

Zhang Y, et al. (2024) CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis. *Cancer cell*, 42(8), 1370.

Liu Q, et al. (2024) Circadian-clock-controlled endocrine and cytokine signals regulate multipotential innate lymphoid cell progenitors in the bone marrow. *Cell reports*, 43(5), 114200.

Xu S, et al. (2024) Development of a PAK4-targeting PROTAC for renal carcinoma therapy: concurrent inhibition of cancer cell proliferation and enhancement of immune cell response. *EBioMedicine*, 104, 105162.

Fan Y, et al. (2023) Targeting LYPLAL1-mediated cGAS depalmitoylation enhances the response to anti-tumor immunotherapy. *Molecular cell*, 83(19), 3520.

Xiao Z, et al. (2023) METTL3-mediated m6A methylation orchestrates mRNA stability and dsRNA contents to equilibrate ?? T1 and ?? T17 cells. *Cell reports*, 42(7), 112684.

Chang YW, et al. (2023) A CSF-1R-blocking antibody/IL-10 fusion protein increases anti-tumor immunity by effectuating tumor-resident CD8+ T cells. *Cell reports. Medicine*, 4(8), 101154.

Potts KS, et al. (2022) Splicing factor deficits render hematopoietic stem and progenitor cells sensitive to STAT3 inhibition. *Cell reports*, 41(11), 111825.

Zeng Q, et al. (2022) Cbl-b restrains priming of pathogenic Th17 cells via the inhibition of IL-6 production by macrophages. *iScience*, 25(10), 105151.